Health-related quality of life with rivaroxaban plus aspirin vs. aspirin alone in chronic stable cardiovascular disease: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial
Authors
Deepak L. Bhatt (ORCID: https://orcid.org/0000-0002-1278-6245)
Salim Yusuf (ORCID: https://orcid.org/0000-0003-4776-5601)
Jiajun Yan (ORCID: https://orcid.org/0000-0001-8966-8709)
Eva Muehlhofer (ORCID: https://orcid.org/0000-0001-8213-232X)
Health-related quality of life with rivaroxaban plus aspirin vs. aspirin alone in chronic stable cardiovascular disease: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial
Deepak L. Bhatt, Salim Yusuf, Jiajun Yan, Eva Muehlhofer et al.
Citations
1 citations
Journal
European Heart Journal Open
Topics
Antiplatelet Therapy and Cardiovascular Diseases
Field-Weighted Citation Impact (FWCI)
0.40
article
Health-related quality of life with rivaroxaban plus aspirin vs. aspirin alone in chronic stable cardiovascular disease: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial
Deepak L. Bhatt, Salim Yusuf, Jiajun Yan, Eva Muehlhofer, Eleanor Pullenayegum, Sonia S. Anand, Jackie Bosch, Álvaro Avezum, John W. Eikelboom, Feng Xie, Yang Wang
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
European Heart Journal OpenVol. 4(5)
Institutions
McMaster University Medical Centre (CA), Hospital for Sick Children (CA), Population Health Research Institute (CA), Policy Analysis (United States) (US), SickKids Foundation (CA), Institute for Clinical Evaluative Sciences (CA), Instituto Dante Pazzanese de Cardiologia (BR), Impact (CA), Bayer (Germany) (DE), Hamilton Health Sciences (CA), McMaster University (CA), Icahn School of Medicine at Mount Sinai (US)